Watson, Amgen team for biosimilars; Epicept takes precaution with Ben Venue-made drug;

> Generics maker Watson Pharmaceuticals ($WPI) and biotech giant Amgen ($AMGN) have announced their foray into the territory of biosimilars, focusing on oncology antibodies. Item

> EpiCept has written European healthcare professionals regarding Ceplene, its leukemia-remission aid manufactured by troubled Ben Venue, reminding them to examine each vial for particles even though regulators have recommended no recall. Item

> A shut-down Pfizer ($PFE) plant in Terra Haute, IN, about 200 miles south of Chicago, is being taken over by an unnamed drugmaker. Story

> The on-again, off-again effort to revive three public vaccine plants in India is on again with the health ministry's approval of $12 million to upgrade one plant--the BCG Lab in Chennai--to WHO manufacturing standards. Item

Xinhuanet reports China will maintain its "iron-handed policy" in fighting counterfeit drugs in the coming year. Report

> AAIPharma Services has named Kevin Flanagan VP for packaging services, overseeing packaging and distribution. Release

> The 245-company-strong pharma manufacturing industry in Bangladesh is plotting to enter U.S. and European markets. Story

> Repligen has acquired Novozymes Biopharma Sweden AB, manufacturer of growth factors used in mammalian cell culture. Release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.